Vitamin K1: Uses, Mechanism, Dosage, Side Effects

What is Vitamin K1?

Vitamin K1, also known by its chemical name phylloquinone, is a fat-soluble vitamin essential for the synthesis of several blood clotting factors. It plays a critical role in the body's hemostasis process, preventing excessive bleeding. While the body can produce some vitamin K through gut bacteria, dietary intake is crucial, and Vitamin K1 is the primary dietary source. It is often referred to as phytonadione in its pharmaceutical form. Generic Vitamin K1 is available, with common brand names including Mephyton and Aquamephyton, though availability can vary by region and formulation.

Unlike other vitamins, vitamin K is not primarily stored in large quantities in the body, making consistent dietary intake or supplementation important. Its deficiency can lead to serious health consequences, particularly related to bleeding. Understanding the role and management of Vitamin K1 is vital in various clinical settings, from neonatology to internal medicine.

Mechanism of Action

Vitamin K1 functions as a cofactor for the enzyme gamma-glutamyl carboxylase (GGCX). This enzyme is crucial for the post-translational modification of specific proteins involved in blood coagulation, collectively known as vitamin K-dependent proteins (VKDPs). The primary VKDPs synthesized in the liver include factors II (prothrombin), VII, IX, and X, as well as proteins C and S.

The carboxylation process, also known as vitamin K epoxidation cycle, is fundamental. In this cycle, vitamin K1 (in its reduced hydroquinone form) acts as an electron donor. Gamma-glutamyl carboxylase catalyzes the addition of a carboxyl group (COOH) to specific glutamate residues on these precursor proteins. This carboxylation converts these glutamate residues into gamma-carboxyglutamate (Gla) residues. The Gla residues are critical because they possess a strong negative charge, enabling the vitamin K-dependent proteins to bind calcium ions (Ca²⁺).

Calcium binding is essential for the proper functioning of these coagulation factors. Once bound to calcium, the VKDPs can anchor themselves to phospholipid surfaces (like those found on activated platelets and endothelial cells) within the coagulation cascade. This localization is vital for the efficient assembly of the various enzyme complexes that lead to the formation of a stable fibrin clot, thereby stopping bleeding.

Without adequate vitamin K, the gamma-glutamyl carboxylase enzyme cannot effectively carboxylate these glutamate residues. This results in the production of inactive or partially active VKDPs, which lack the ability to bind calcium and participate effectively in the coagulation cascade. Consequently, blood clotting is impaired, leading to an increased risk of bleeding.

The Vitamin K Epoxide Cycle

The mechanism is further elaborated by the vitamin K epoxide cycle:

• Carboxylation: Vitamin K1 (hydroquinone form) is oxidized to vitamin K1-2,3-epoxide during the carboxylation reaction.
• Epoxide Reduction: Vitamin K1-2,3-epoxide is then reduced back to vitamin K1 quinone by epoxide reductases.
• Quinone Reduction: Finally, vitamin K1 quinone is reduced to the active hydroquinone form by a vitamin K reductase, completing the cycle and regenerating the cofactor for further carboxylation.

This cyclical process ensures that a small amount of vitamin K can be reused multiple times, highlighting its catalytic role. Disruptions in this cycle, such as those caused by anticoagulant medications like warfarin, directly impact vitamin K-dependent coagulation.

Clinical Uses & Indications

Vitamin K1 is primarily indicated for the prevention and treatment of vitamin K deficiency bleeding (VKDB), a condition that can affect newborns, infants, and adults. Its use is crucial in situations where the body's ability to utilize or absorb vitamin K is compromised.

FDA-Approved Uses and Common Indications:

• Prevention of Vitamin K Deficiency Bleeding (VKDB) in Newborns: This is a standard practice worldwide. A single intramuscular dose of Vitamin K1 is administered to all newborns shortly after birth to prevent hemorrhagic disease of the newborn, a potentially life-threatening condition caused by low vitamin K levels.
• Treatment of Vitamin K Deficiency: Vitamin K1 is used to correct deficiencies arising from various causes, including:
  • Malabsorption syndromes (e.g., celiac disease, cystic fibrosis, Crohn's disease, short bowel syndrome)
  • Biliary obstruction or liver disease
  • Chronic use of certain medications (e.g., anticonvulsants, some antibiotics)
  • Poor dietary intake in specific populations (e.g., elderly, alcoholics)
• Reversal of Anticoagulation: Vitamin K1 is a critical antidote for excessive anticoagulation caused by warfarin (Coumadin) or other vitamin K antagonist oral anticoagulants (VKAOs). It can be administered orally or intravenously to reverse the effects of these drugs and reduce the risk of bleeding. The speed of reversal depends on the route of administration and the dose used.
• Hemorrhagic Condition Associated with Malabsorption: Used to treat bleeding tendencies in patients with conditions that impair fat absorption, and thus vitamin K absorption.

While the FDA approves specific indications, Vitamin K1 is also used off-label in certain clinical scenarios, always under medical supervision. Its role in hematology is indispensable for managing bleeding disorders related to vitamin K metabolism.

Dosage & Administration

The dosage and administration of Vitamin K1 vary significantly depending on the indication, patient age, and clinical condition. It is crucial to follow physician's recommendations for optimal therapeutic outcomes.

Common Dosage Forms:

• Oral Tablets: Available in various strengths (e.g., 5 mg). This is often the preferred route for chronic vitamin K deficiency or for reversing warfarin effects when immediate and rapid reversal is not critical.
• Injectable Solution: Typically available for intramuscular (IM), subcutaneous (SC), or intravenous (IV) administration. The IV route is usually reserved for urgent situations requiring rapid correction of coagulopathy due to vitamin K deficiency, particularly when oral administration is not feasible or effective. IV administration requires careful monitoring due to potential adverse reactions.
• Oral Solution/Drops: Often used for neonatal prophylaxis.

Typical Dosing Guidelines:

• Neonatal Prophylaxis: A single IM dose of 0.5 mg to 1 mg is typically given within the first hour of life. Premature infants may require 0.3 mg IM.
• Treatment of Vitamin K Deficiency (Adults): Oral doses can range from 5 mg to 25 mg daily, sometimes divided into multiple doses. For more severe deficiency or impaired absorption, parenteral administration might be necessary, with doses ranging from 10 mg to 25 mg IM or SC, potentially repeated. IV administration is usually reserved for emergencies, with doses typically ranging from 5 mg to 25 mg, administered slowly.
• Reversal of Warfarin:
  • For mild over-anticoagulation (high INR but no significant bleeding): Oral Vitamin K1, 1 mg to 5 mg.
  • For significant bleeding: Oral or IV Vitamin K1, 5 mg to 10 mg or higher, often alongside fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) for rapid reversal. IV administration should be slow (e.g., over 30 minutes) to minimize risk.

Important Considerations:

• Parenteral formulations often contain preservatives (e.g., benzyl alcohol) which should be avoided in neonates.
• Absorption of oral Vitamin K1 can be enhanced by consuming it with a meal containing fat.
• The onset of action for oral Vitamin K1 can take 6-24 hours, while IV administration may show effects within hours.
• Regular monitoring of prothrombin time (PT) or INR is essential to assess the effectiveness of treatment and guide further dosing.

Side Effects & Safety

Vitamin K1 is generally well-tolerated when administered appropriately. However, like all medications, it can cause side effects, and certain patient populations require caution.

Common Side Effects:

When taken orally, Vitamin K1 has a low incidence of side effects. Some individuals might experience mild gastrointestinal upset, such as nausea or indigestion. If administered intramuscularly or subcutaneously, there might be localized pain, swelling, or bruising at the injection site.

Serious Side Effects and Precautions:

• Hypersensitivity Reactions: Although rare, anaphylactic reactions can occur, particularly with rapid intravenous administration of parenteral formulations. Symptoms may include flushing, dizziness, shortness of breath, sweating, chest pain, and potentially collapse. For this reason, IV administration should be done slowly and under close medical supervision.
• Benzyl Alcohol Toxicity: Some parenteral formulations contain benzyl alcohol as a preservative. This can be toxic, especially in neonates and premature infants, leading to gasping syndrome. Therefore, formulations free of benzyl alcohol should be used in this population.
• Ineffectiveness in Severe Liver Disease: Vitamin K1 is synthesized in the liver. In cases of severe hepatocellular disease, the liver may be unable to utilize administered Vitamin K1 effectively, rendering it less useful for correcting coagulopathy.
• Paradoxical Thrombosis: In rare instances, rapid IV administration of Vitamin K1, especially in patients with severe liver disease or those receiving anticoagulants, has been associated with paradoxical thromboembolic events.

Contraindications:

• Known Hypersensitivity: Patients with a known hypersensitivity to Vitamin K1 or any component of the formulation should not receive the drug.
• Dependence on Oral Anticoagulation: In patients who are therapeutically anticoagulated with warfarin for conditions like mechanical heart valves or recurrent venous thromboembolism, the administration of Vitamin K1 must be carefully managed. Abrupt or excessive use can undermine the intended anticoagulation, potentially increasing the risk of thrombosis. Decisions to administer Vitamin K1 in these patients are made on a risk-benefit basis, often with close monitoring and consideration of alternative reversal agents or strategies.

It is essential for patients to inform their healthcare provider about any pre-existing medical conditions, particularly liver disease or allergies, before starting Vitamin K1 therapy.

Drug Interactions

Vitamin K1 can interact with several medications, altering their efficacy or increasing the risk of adverse events. Awareness of these interactions is crucial for safe and effective patient management.

Key Drug Interactions:

• Warfarin and Other Vitamin K Antagonists (VKAs): This is the most significant interaction. Vitamin K1 antagonizes the anticoagulant effect of warfarin and other VKAs (e.g., acenocoumarol, phenprocoumon). Concurrent administration requires careful balancing. If Vitamin K1 is given to reverse warfarin's effects, it can lead to a rebound increase in INR if the underlying indication for anticoagulation is still present. Conversely, chronic low-dose Vitamin K1 supplementation (e.g., from multivitamins) might slightly reduce warfarin's efficacy, though this is generally less of a concern than acute administration.
• Antibiotics: Certain broad-spectrum antibiotics can reduce vitamin K synthesis by gut flora, potentially increasing the risk of vitamin K deficiency. While this doesn't typically contraindicate Vitamin K1 use, it highlights a potential contributing factor to deficiency.
• Cholestyramine and Colestipol: These bile acid sequestrants can impair the absorption of fat-soluble vitamins, including Vitamin K1. If concurrent use is necessary, administration of Vitamin K1 should be spaced several hours apart from these agents.
• Orlistat: This weight-loss medication inhibits fat absorption and can similarly reduce the absorption of Vitamin K1. Patients taking orlistat may require vitamin K supplementation.
• Mineral Oil: When taken orally, mineral oil can interfere with the absorption of fat-soluble vitamins, including Vitamin K1.
• Rifampin and Phenytoin: Some anticonvulsants like phenytoin, and the antibiotic rifampin, have been reported to potentially increase the metabolism of vitamin K, theoretically increasing the need for vitamin K. However, this interaction is generally considered less clinically significant than others.

Patients on anticoagulation therapy should never adjust their vitamin K intake or take supplements without consulting their physician. Similarly, individuals taking other medications should report all current medications and supplements to their healthcare provider to identify potential interactions.

Molecular Properties

Vitamin K1, or phylloquinone, is a specific form of vitamin K characterized by its chemical structure. It belongs to the naphthoquinone family and is distinguished by a phytol side chain.

Key Molecular Characteristics:

• Chemical Name: Phylloquinone
• Synonyms: Vitamin K1, Phytonadione
• Molecular Formula: C₃₁H₄₆O₂
• Molecular Weight: Approximately 450.7 g/mol
• Structure Description: Vitamin K1 consists of a 2-methyl-1,4-naphthoquinone ring system attached to a phytyl side chain at the 3-position. The phytyl group is a saturated C16 isoprenoid alcohol derivative. The molecule is hydrophobic due to the long, nonpolar phytyl tail, which facilitates its incorporation into cell membranes and chylomicrons for transport. The naphthoquinone ring is the active part of the molecule involved in the carboxylation cycle.
• SMILES Notation: CC(/C=C/CC(C)CCCC(C)CCCC(C)C)CC1=C(C)C(=O)c2ccccc2C1=O

The SMILES string provides a line notation representation of the molecule's structure. It describes the arrangement of atoms and bonds, allowing for computational analysis and identification. Specifically, it indicates a branched alkyl chain (the phytyl group, represented by the repeated (C)CCCC sequences) attached to a substituted naphthoquinone core (the aromatic rings with carbonyl groups).

The fat-soluble nature of Vitamin K1 is directly related to its molecular structure, influencing its absorption, transport, and distribution within the body. It is absorbed in the small intestine along with dietary fats and transported via the lymphatic system in chylomicrons.

Analyze Vitamin K1 with MolForge

Understanding the intricate molecular properties, interactions, and potential applications of Vitamin K1 is fundamental in pharmaceutical research and drug discovery. While this article provides a comprehensive overview, advanced computational tools can unlock deeper insights.

MolForge's AI-powered platform offers state-of-the-art capabilities for exploring molecules like Vitamin K1. Researchers can leverage our tools to:

• Visualize and analyze complex molecular structures, including detailed examination of the naphthoquinone ring and phytyl chain.
• Predict potential drug-target interactions and binding affinities.
• Investigate metabolic pathways and potential toxicity profiles.
• Identify novel analogs or derivatives with improved pharmacological properties.
• Streamline the drug discovery process from initial hypothesis to preclinical development.

Dive deeper into the science behind Vitamin K1 and countless other compounds. Explore the future of molecular discovery by visiting the MolForge dashboard today and harness the power of AI for your research endeavors.